Investigational drug · Phase 2
RC108
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-Small Cell Lung Cancer, Digestive Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "RC108"
First trial start
2022
Nov 11, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RC108", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer
- Digestive Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RC108" as an intervention, largest first.
- RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLCStatus unknown
RemeGen Co., Ltd.Industry
NCT05821933 · 106 participants (planned) · Start Sep 7, 2023 · Primary completion Sep 1, 2025
Drug: RC108 · For: NSCLC
Sites: Beijing, China
RemeGen Co., Ltd.Industry
NCT06962865 · 80 participants (planned) · Start Jun 30, 2025 · Primary completion May 31, 2026
Drug: RC108; Furmonertinib Mesilate Tablets Monotherapy · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Binzhou, China; Changchun, China · 34 sites in all
RemeGen Co., Ltd.Industry
NCT04617314 · 67 participants · Start Mar 10, 2021 · Primary completion Dec 31, 2025
Drug: RC108 · For: Solid Tumor
Sites: Beijing, China; Changsha, China; Changchun, China · 4 sites in all
RemeGen Co., Ltd.Industry
NCT05628857 · 29 participants · Start Nov 11, 2022 · Primary completion Dec 31, 2025
Drug: RC108 · For: Digestive Cancer
Sites: Beijing, China
Ronald HoffmanAcademic, hospital or other
NCT00940784 · 0 participants · Start Jun 2009 · Primary completion Jan 2011
Drug: Clopidogrel (Plavix); Placebo and 1 more · For: Polycythemia Vera
Newest research
PubMed records naming it or its code names, newest first.
- A multiscale quantitative systems pharmacology platform for early screening of MMAE-based antibody-drug conjugates.
Li Q, Wang L, Bi S, et al. · Eur J Pharm Sci 2026
- Lactococcus lactis subsp lactis CRL1655 and Schleiferilactobacillus perolens CRL1724 inhibit the adherence of common bovine mastitis pathogens to mammary gland cells, without causing histological changes in the mammary gland.
Berardo N, Giraudo J, Magnano G, et al. · J Appl Microbiol 2022
- Avirulence and immunogenicity in mice of a bovine mastitis Staphylococcus aureus mutant.
Bogni C, Segura M, Giraudo J, et al. · Can J Vet Res 1998
Also in development for Non-Small Cell Lung Cancer
- SKB264MK-2870, Sacituzumab TirumotecanPhase 353 trials
Merck & Co. · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer, Cervical Cancer
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- BL-M07D1Phase 317 trials
Sichuan Baili Pharmaceutical Co., Ltd. · HER2-positive Breast Cancer, Non-squamous Non-small Cell Lung Cancer, Her2-positive/Low-expression Urinary and Digestive Tract Tumors
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.